SCHEMBL13833692

SCHEMBL13833692

CC(=O)Nc1sc2c(c1-c1nc3ccccc3s1)CCN(Cc1ccc(F)cc1)C2

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 9/20 0.69
KDM4E B2RXH2 3/20 0.65
USP2 O75604 2/20 0.65
MEN1 O00255 2/20 0.65
HTT P42858 2/20 0.65
KMT2A Q03164 2/20 0.65
NPC1 O15118 2/20 0.65
POLB P06746 1/20 0.65
RECQL P46063 1/20 0.65
RAB9A P51151 1/20 0.65
BLM P54132 1/20 0.65
UHRF1 Q96T88 2/20 0.64
LMNA P02545 2/20 0.62
RXFP1 Q9HBX9 1/20 0.62
ATM Q13315 1/20 0.59
MYC P01106 2/20 0.57
ALDH1A1 P00352 2/20 0.56
MAPT P10636 2/20 0.56
TP53 P04637 1/20 0.56
HPGD P15428 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1494800 0.93 APEX1 (0.73) APEX1KDM4EUSP2MEN1HTT
SCHEMBL13833693 0.91 APEX1 (0.70) APEX1KDM4EUSP2MEN1HTT
SCHEMBL13833590 0.87 APEX1 (0.77) APEX1KDM4EUSP2MEN1HTT
Hydrochloric Acid SCHEMBL14777279 0.86 APEX1 (0.76) APEX1KDM4EUSP2MEN1HTT
SCHEMBL14788066 0.86 APEX1 (0.76) APEX1KDM4EUSP2MEN1HTT
SCHEMBL13833691 0.85 UHRF1 (0.72) APEX1KDM4EUSP2MEN1HTT
SCHEMBL13833603 0.85 APEX1 (0.75) APEX1KDM4EUSP2MEN1HTT
SCHEMBL14788092 0.85 APEX1 (0.78) APEX1KDM4EUSP2MEN1HTT
SCHEMBL13833688 0.84 APEX1 (0.75) APEX1KDM4EUSP2MEN1HTT
Hydrochloric Acid SCHEMBL14777941 0.84 APEX1 (0.73) APEX1KDM4EUSP2MEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. 2013-03-21 US disclosed
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. 2013-03-21 US disclosed
WO-2012154888-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. (US) 2012-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS HSPA5, PSMG3, VCP APEX1 2669/4885KDM4E 3155/4885USP2 1350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.